Niraparib Maintenance Through the Patient's Eyes: Patient-Reported Outcomes From the PRIMA Study
In this article
Quality of Life Data During Niraparib Maintenance: How Much Reassurance Does the PRIMA Study Bring to Patients' Voices?
Success in Maintenance Treatment Means More Than Delaying Recurrence
In ovarian cancer treatment, the response achieved after surgery and platinum-based chemotherapy is often fragile. In a substantial proportion of patients, the disease returns over time. Maintenance treatment is therefore a strategic period aimed at preserving the initial response for as long as possible. PARP inhibitors have become one of the most important treatment classes in this period, particularly in tumors with a BRCA mutation or homologous recombination deficiency.
However, maintenance treatment is a different psychological and clinical setting from chemotherapy. The patient often feels that active chemotherapy has ended, their hair has begun to grow back and they are returning to work and family life. Starting long-term tablet treatment at precisely this point can create the feeling: “Has the disease really ended, or am I still receiving treatment?” Patient-reported outcomes, meaning data in which patients directly report the symptoms they experience and their quality of life, are therefore at least as valuable in maintenance treatment as conventional toxicity tables.
Why Are Patient-Reported Outcomes Needed?
In clinical studies, side effects are usually graded by the physician. However, nausea, constipation, fatigue or loss of appetite recorded by the physician as “grade 1-2” may seriously disrupt the rhythm of everyday life for the patient. Patient-reported outcomes fill this gap; they show how treatment affects the patient's own experience, beyond laboratory and imaging results.
This long-term PRIMA analysis is important for precisely this reason: it separately examines in the HRD-positive and HRp groups whether niraparib maintenance impairs patients' overall health-related quality of life over the long term.
PARP Inhibitors: From the Concept of Synthetic Lethality to Maintenance Treatment
The effect of PARP inhibitors in ovarian cancer rests on weaknesses in DNA repair mechanisms. Homologous recombination repair is impaired in tumors with a BRCA1/2 mutation or, more broadly, HRD positivity. Suppressing the PARP pathway as well in these cells makes the cancer cell unable to repair DNA damage. For this biological relationship, the term synthetic lethality is used.
Niraparib was evaluated in the PRIMA/ENGOT-OV26/GOG-3012 study as first-line maintenance treatment for patients with newly diagnosed advanced ovarian cancer who had a complete or partial response to platinum-based chemotherapy. The initial analyses showed a progression-free survival benefit; this benefit was more pronounced in HRD-positive patients and more limited in the HRp group, meaning the homologous recombination sufficient/proficient group.
What Do HRD and HRp Mean?
HRD means homologous recombination deficiency and indicates that the tumor cell's high-fidelity DNA repair capacity is impaired. HRD-positive tumors tend to derive greater benefit from PARP inhibitors. HRp refers to the group in which homologous recombination repair is relatively preserved; the benefit of PARP inhibitors in this group is more limited and debated.
A Note on Current Approval and Clinical Reality
The PRIMA data have shown that niraparib has meaningful value as maintenance treatment, particularly in HRD-positive patients. However, the lack of a clear OS advantage in the overall population in the final overall survival analyses and the FDA's restriction of niraparib's first-line maintenance indication to HRD-positive patients in 2025 remind us that this treatment should now be offered to more selected patients rather than “every patient.”
What Did the SGO 2026 Analysis Ask?
The subanalysis presented at SGO 2026 assessed the patient-reported outcomes in the PRIMA final analysis separately in the HRD and HRp populations. The aim was to understand whether niraparib maintenance impaired patients' overall health-related quality of life in the long term compared with placebo.
The researchers used four validated scales: EORTC QLQ-C30 assessed overall cancer-related quality of life; EORTC QLQ-OV28 assessed ovarian cancer-specific symptoms and functional domains; EQ-5D-5L VAS assessed general health status; and FOSI assessed ovarian cancer-related symptoms.
QLQ-C30
Assesses domains such as overall quality of life, physical functioning, fatigue, nausea and vomiting, pain and social functioning in patients with cancer.
QLQ-OV28
Focuses on ovarian cancer-specific domains such as abdominal symptoms, hormonal effects, body image and attitudes toward treatment/disease.
EQ-5D-5L VAS and FOSI
Captures the patient's direct experience of perceived general health and the burden of ovarian cancer-related symptoms.
When Were the Measurements Taken?
Patient-reported outcomes were assessed at baseline, every 8 weeks during the first 56 weeks and then every 12 weeks until treatment discontinuation. Measurements were also taken at the end of treatment and at 4, 8, 12 and 24 weeks after treatment. Questionnaire completion rates above 89% through cycle 24 are an important strength in terms of data reliability.
Key Findings of the Analysis
- Overall health-related quality of life: No significant difference was observed between niraparib and placebo in the HRD and HRp groups.
- EQ-5D-5L VAS: An upward trend was observed over time in both treatment arms, suggesting that perceived general health did not worsen during treatment.
- Gastrointestinal symptoms: Loss of appetite, nausea and vomiting, and constipation were more pronounced in the niraparib arm, particularly early on.
- Improvement over time: Most early gastrointestinal differences diminished or disappeared over time; constipation remained numerically more frequent in the niraparib arm.
- Attitudes toward disease/treatment: A signal of improvement over time was observed in the QLQ-OV28 domain of attitudes toward disease and treatment.
Overall Quality of Life: Niraparib Does Not Appear Worse Than Placebo
The main finding of the analysis is simple but clinically important: overall health-related quality of life measurements in the HRD and HRp subgroups were similar in the niraparib and placebo arms. This answers a frequently asked question about maintenance treatment: “Does long-term tablet treatment given to delay recurrence impair the patient's quality of life?” In this analysis, the answer appears to be no.
| Domain | HRD population | HRp population | Clinical significance for niraparib | Interpretation |
|---|---|---|---|---|
| Overall health-related quality of life | No significant difference between niraparib and placebo | No significant difference between niraparib and placebo | It appears not to markedly impair overall quality of life in the long term | Reassuring for the patient experience when deciding on maintenance treatment. |
| Loss of appetite | More pronounced with niraparib early on | More pronounced with niraparib early on | Patient education and symptom management are needed at the start | The difference mostly diminishes over time. |
| Nausea/vomiting | More pronounced with niraparib early on | More pronounced with niraparib early on | The antiemetic approach and dose tolerability should be monitored | The initial weeks are the most critical period. |
| Constipation | Lower scores in favor of placebo | Lower scores in favor of placebo | A sustained management plan may be needed for patients receiving niraparib | May last longer than other GI symptoms. |
| Attitudes toward disease/treatment | Trend toward improvement over time | Trend toward improvement over time | Patients may perceive the treatment process as more tolerable over time | Good information and expectation management can strengthen this domain. |
It Can Be Challenging at First, but Most Symptoms Ease Over Time
The most pronounced differences with niraparib were seen in gastrointestinal symptoms. Loss of appetite, nausea/vomiting and constipation were worse in the niraparib arm early on. However, most symptoms such as loss of appetite and nausea/vomiting diminished or disappeared over time. Constipation remained numerically more frequent in the niraparib arm than with placebo.
This finding is highly valuable clinically, because a patient starting maintenance treatment may interpret symptoms in the first weeks as “this treatment is not helping me.” Yet this analysis shows that some early symptoms may ease over time. Open discussion before treatment, early supportive treatment and close monitoring may therefore improve the drug's tolerability.
A Practical Note on Symptom Management
- Nausea: A prophylactic or early antiemetic approach may be needed at the start of treatment.
- Loss of appetite: Small, frequent meals, nutritional counseling and weight monitoring are important.
- Constipation: Fluid intake, balanced fiber intake, movement and a laxative plan when needed should be discussed at the start of treatment.
- Hematological toxicity: Monitoring platelets, hemoglobin and neutrophils is also important for niraparib; although this PRO analysis focuses on quality of life, blood counts should not be neglected in clinical follow-up.
How Should This Be Discussed With a Patient?
“This treatment is given to reduce the risk of recurrence. Symptoms such as nausea, loss of appetite or constipation may occur in the first weeks; many of them may diminish over time, and we have effective supportive treatments to manage them. However, whether the treatment is suitable for you will be assessed together with your tumor's HRD status, general health, blood counts and your priorities.”
The Quality of Life Data Are Positive, but Selection for Efficacy Should Be Based on Biomarkers
In this new analysis, the absence of impairment in overall quality of life with niraparib in the HRD and HRp groups is important, reassuring information. However, quality of life data do not expand the treatment's biological scope of efficacy. In other words, the statement “quality of life is not impaired in HRp patients either” does not mean “clinical benefit is at the same level in HRp patients.”
The complete PRIMA dataset has shown that the benefit of niraparib is stronger particularly in HRD-positive tumors. The FDA's narrower definition of the indication as HRD-positive first-line maintenance in 2025 is therefore also a critical milestone. In current clinical practice, patient selection should consider the HRD test, BRCA status, platinum response, previous treatment tolerability, performance status, hematological reserve and the patient's quality of life expectations together.
| Topic | HRD-positive patient | HRp patient | Current clinical interpretation |
|---|---|---|---|
| Biological rationale | Greater sensitivity to PARP inhibitors | More limited sensitivity to PARP inhibitors | HRD testing plays a central role in treatment selection. |
| PRIMA efficacy message | More pronounced PFS benefit | More limited PFS benefit | Efficacy should be interpreted separately by biomarker status. |
| Quality of life message | Niraparib did not impair overall HRQoL compared with placebo | Niraparib did not impair overall HRQoL compared with placebo | PRO data are reassuring in terms of tolerability. |
| Approval/practice framework | Consistent with the FDA's current first-line maintenance indication | For newly initiated treatment, the FDA has considered the benefit-risk balance unfavorable | In an HRp patient, the decision should be much more selective and depend on the country's approval. |
Truecheck Note
The message in the headline of this news report that “quality of life is preserved regardless of HRD status” is correct; however, this statement should not be read as meaning that the treatment indication is independent of HRD. The quality of life subanalysis supports tolerability and the patient experience. Treatment selection should be assessed together with efficacy, overall survival data, the approval text and biomarker status.
The Toxicity Seen by the Physician and the Burden Experienced by the Patient Are Not the Same
This analysis shows that the PRIMA study should not be viewed merely as a “tolerability addendum.” Patient-reported outcomes open a separate window onto the real-life meaning of maintenance treatment. A drug's laboratory toxicity may be manageable; however, if taking the drug every day makes the patient feel persistently ill, tired, without appetite or affected by disrupted bowel habits, the treatment experience is different.
The long-term patient-reported PRIMA data suggest that niraparib maintenance does not leave a lasting negative mark on overall quality of life. This strengthens the discussion of risks and benefits, particularly in patients who are HRD-positive and have responded to platinum.
Questions to Ask During the Clinical Consultation
- What are the HRD and BRCA results? They establish the biological basis of treatment selection.
- How did the patient respond to platinum treatment? The value of maintenance treatment is closely related to platinum sensitivity.
- Are the baseline blood counts suitable? Niraparib requires close monitoring for hematological toxicity.
- What does the patient most want to preserve in everyday life? The maintenance treatment decision should be made together with quality of life priorities.
- Has a plan been made for early symptoms? A management plan prepared in advance for nausea, loss of appetite and constipation can improve treatment adherence.
A More Selective, More Openly Discussed and More Personalized Maintenance Period
Academic Assessment
While the PRIMA/ENGOT data show that niraparib has meaningful value as maintenance treatment, particularly in HRD-positive patients, the lack of a clear overall survival advantage in the final analysis and the FDA's narrower definition of the indication as HRD-positive first-line maintenance remind us that this treatment should now be offered to more selected patients rather than “every patient.”
The absence of a negative signal in the patient-reported quality of life data is important, because our goal in maintenance treatment is not only to delay recurrence but also to preserve the patient's ability to return confidently to life after chemotherapy.
The most reasonable future perspective for niraparib is therefore a more personalized maintenance treatment approach built on biomarker-based selection, careful side effect management and open shared decision-making with the patient.
The Message for Niraparib: Reassuring for Quality of Life, Requiring Greater Care in Patient Selection
The patient-reported quality of life subanalysis of PRIMA presented at SGO 2026 shows that niraparib maintenance does not adversely affect overall health-related quality of life compared with placebo in the HRD and HRp populations. Although gastrointestinal symptoms such as loss of appetite, nausea/vomiting and constipation were more pronounced in the niraparib arm early on, most of these differences diminished or disappeared over time. Constipation stands out as a more persistent issue requiring management.
These data support the tolerability of niraparib as long-term maintenance treatment in well-selected patients. However, they must also remind us that the current PARP inhibitor era requires more careful patient selection. PRIMA's final OS data and the FDA's narrowing of the indication in 2025 have shifted niraparib's clinical position toward biomarker-based decision-making, side effect management and joint discussion of patient priorities.
The future of maintenance treatment in ovarian cancer will be shaped by answers not only to “which drug?” but also to “which patient, which biology, which quality of life goal and which balance of risks and benefits?” This new quality of life analysis for niraparib is a valuable part of the equation that strengthens the patient experience component.
References
- The ASCO Post. Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status. 2026.
- Backes F, Barretina-Ginesta M-P, Monk B et al. Patient-reported outcomes from the final analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial. 2026 SGO Annual Meeting on Women’s Cancer. Abstract 331.
- U.S. FDA. ZEJULA (niraparib) Prescribing Information. 2025 label update.
- GSK. Important Prescribing Information: ZEJULA U.S. indication update following final PRIMA OS analysis. June 2025.
- drozdogan.com. A New View of PARP Inhibitors After the PRIMA Study Overall Survival Results. 17 October 2025.
- drozdogan.com. What Is HRD Testing and Why Is It Needed? A Personalized Compass in Ovarian Cancer Treatment. 27 October 2025.
- Monk BJ et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: long-term PRIMA/ENGOT-OV26/GOG-3012 data. Gynecologic Oncology. 2024.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.